Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation.
COVID-19
/ diagnosis
COVID-19 Testing
/ methods
Epidemics
/ prevention & control
Hot Temperature
Humans
Nasopharynx
/ virology
RNA, Viral
/ genetics
Reagent Kits, Diagnostic
Reproducibility of Results
Reverse Transcriptase Polymerase Chain Reaction
/ methods
SARS-CoV-2
/ genetics
Sensitivity and Specificity
Specimen Handling
/ methods
Virus Inactivation
Workflow
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2021
accepted:
17
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
5
10
2021
Statut:
epublish
Résumé
There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform manual processing. We provide multiple workflows for SARS-CoV-2 nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral RNA Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind Viral DNA/RNA 96 Kit (Omega Bio-tek). We also compared One-step RT-qPCR reagents: TaqMan Fast Virus 1-Step Master Mix (FastVirus, ThermoFisher Scientific), qPCRBIO Probe 1-Step Go Lo-ROX (PCR Biosystems) and Luna® Universal Probe One-Step RT-qPCR Kit (Luna, NEB). We used primer-probes that detect viral N (EUA CDC) and RdRP. RNA extraction methods provided similar results, with Beckman performing better with our primer-probe combinations. Luna proved most sensitive although overall the three reagents did not show significant differences. N detection was more reliable than that of RdRP, particularly in samples with low viral titres. Importantly, we demonstrated that heat treatment of nasopharyngeal swabs at 70°C for 10 or 30 min, or 90°C for 10 or 30 min (both original variant and B 1.1.7) inactivated SARS-CoV-2 employing plaque assays, and had minimal impact on the sensitivity of the qPCR in clinical samples. These findings make SARS-CoV-2 testing portable in settings that do not have CL-3 facilities. In summary, we provide several testing pipelines that can be easily implemented in other laboratories and have made all our protocols and SOPs freely available at https://osf.io/uebvj/.
Identifiants
pubmed: 34525109
doi: 10.1371/journal.pone.0256813
pii: PONE-D-21-12761
pmc: PMC8443028
doi:
Substances chimiques
RNA, Viral
0
Reagent Kits, Diagnostic
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256813Subventions
Organisme : Medical Research Council
ID : MR/S023747/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S000844/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106223/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102871/Z/13/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15068
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U54 AI150472
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI076119
Pays : United States
Organisme : Medical Research Council
ID : MR/S009191/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R37 AI076119
Pays : United States
Organisme : Wellcome Trust
ID : 218537/Z/19/Z
Pays : United Kingdom
Commentaires et corrections
Type : UpdateOf
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Euro Surveill. 2020 Apr;25(14):
pubmed: 32290902
J Virol Methods. 2021 Jan;287:113969
pubmed: 32918932
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
PLoS Biol. 2020 Oct 2;18(10):e3000896
pubmed: 33006983
Lancet Microbe. 2020 Aug;1(4):e146
pubmed: 33521712
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32269100
J Gen Virol. 2021 Mar;102(3):
pubmed: 33416462
PLoS One. 2021 Feb 26;16(2):e0247792
pubmed: 33635936
J Infect Dis. 2020 Oct 1;222(9):1462-1467
pubmed: 32798217
Nat Microbiol. 2020 Dec;5(12):1452-1454
pubmed: 33139885
Biotechnol Bioeng. 2021 May;118(5):2067-2075
pubmed: 33615450
Nat Biotechnol. 2020 Jul;38(7):791-797
pubmed: 32555529
Emerg Microbes Infect. 2020 Dec;9(1):1393-1396
pubmed: 32552549
Clin Chem. 2020 Jun 1;66(6):794-801
pubmed: 32246822
PLoS Biol. 2020 Dec 15;18(12):e3001030
pubmed: 33320856
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
J Public Health (Oxf). 2021 Apr 12;43(1):82-88
pubmed: 33124664
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
J Clin Virol. 2020 Jul;128:104423
pubmed: 32416598
Eur J Immunol. 2021 Jan;51(1):13-16
pubmed: 33616905